---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-138224"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:47:46.098465+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024

## Summary
- Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.
- Initial base salary $480,000, discretionary bonus target 40%; receives 40,875 RSUs and options for 245,250 shares.
- Rasbach previously CFO at Zentalis, portfolio manager at Eventide, and analyst at T. Rowe Price and Cowen.
- Severance includes 12 months salary, COBRA, and potential equity acceleration; if over $120M financing, unvested equity may continue vesting 24 months.

## SEC filing metadata
- accession: 0000950170-24-138224
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/0000950170-24-138224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/lxeo-20241218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-138224
- JSON: https://secwatch.observer/filing/0000950170-24-138224.json
- Plain text: https://secwatch.observer/filing/0000950170-24-138224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.